AMICUS THERAPEUTICS INC (FOLD) Fundamental Analysis & Valuation
NASDAQ:FOLD • US03152W1099
14.36 USD
-0.01 (-0.07%)
At close: Mar 10, 2026
14.36 USD
0 (0%)
After Hours: 3/10/2026, 8:26:44 PM
This FOLD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
Overall FOLD gets a fundamental rating of 4 out of 10. We evaluated FOLD against 519 industry peers in the Biotechnology industry. FOLD has only an average score on both its financial health and profitability. FOLD has a decent growth rate and is not valued too expensively.
1. FOLD Profitability Analysis
1.1 Basic Checks
- FOLD had negative earnings in the past year.
- In the past year FOLD had a positive cash flow from operations.
- FOLD had negative earnings in each of the past 5 years.
- FOLD had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of -2.85%, FOLD belongs to the top of the industry, outperforming 86.90% of the companies in the same industry.
- FOLD's Return On Equity of -9.89% is amongst the best of the industry. FOLD outperforms 87.09% of its industry peers.
- The Return On Invested Capital of FOLD (3.83%) is better than 90.37% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.85% | ||
| ROE | -9.89% | ||
| ROIC | 3.83% |
ROA(3y)-9.83%
ROA(5y)-17.97%
ROE(3y)-44.48%
ROE(5y)-81.46%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- FOLD's Operating Margin of 5.44% is amongst the best of the industry. FOLD outperforms 89.60% of its industry peers.
- Looking at the Gross Margin, with a value of 88.50%, FOLD belongs to the top of the industry, outperforming 89.98% of the companies in the same industry.
- In the last couple of years the Gross Margin of FOLD has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 5.44% | ||
| PM (TTM) | N/A | ||
| GM | 88.5% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.09%
GM growth 5Y0.1%
2. FOLD Health Analysis
2.1 Basic Checks
- FOLD has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
- Compared to 1 year ago, FOLD has more shares outstanding
- The number of shares outstanding for FOLD has been increased compared to 5 years ago.
- FOLD has a better debt/assets ratio than last year.
2.2 Solvency
- Based on the Altman-Z score of 1.27, we must say that FOLD is in the distress zone and has some risk of bankruptcy.
- FOLD has a Altman-Z score of 1.27. This is in the better half of the industry: FOLD outperforms 62.24% of its industry peers.
- The Debt to FCF ratio of FOLD is 13.15, which is on the high side as it means it would take FOLD, 13.15 years of fcf income to pay off all of its debts.
- The Debt to FCF ratio of FOLD (13.15) is better than 90.75% of its industry peers.
- FOLD has a Debt/Equity ratio of 1.43. This is a high value indicating a heavy dependency on external financing.
- Looking at the Debt to Equity ratio, with a value of 1.43, FOLD is doing worse than 77.46% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.43 | ||
| Debt/FCF | 13.15 | ||
| Altman-Z | 1.27 |
ROIC/WACC0.43
WACC8.94%
2.3 Liquidity
- FOLD has a Current Ratio of 2.84. This indicates that FOLD is financially healthy and has no problem in meeting its short term obligations.
- The Current ratio of FOLD (2.84) is worse than 66.28% of its industry peers.
- FOLD has a Quick Ratio of 1.88. This is a normal value and indicates that FOLD is financially healthy and should not expect problems in meeting its short term obligations.
- With a Quick ratio value of 1.88, FOLD is not doing good in the industry: 76.49% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.84 | ||
| Quick Ratio | 1.88 |
3. FOLD Growth Analysis
3.1 Past
- FOLD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 58.33%, which is quite impressive.
- The Revenue has grown by 20.05% in the past year. This is a very strong growth!
- The Revenue has been growing by 19.44% on average over the past years. This is quite good.
EPS 1Y (TTM)58.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-90%
Revenue 1Y (TTM)20.05%
Revenue growth 3Y24.43%
Revenue growth 5Y19.44%
Sales Q2Q%23.72%
3.2 Future
- Based on estimates for the next years, FOLD will show a very strong growth in Earnings Per Share. The EPS will grow by 107.92% on average per year.
- The Revenue is expected to grow by 18.18% on average over the next years. This is quite good.
EPS Next Y534.7%
EPS Next 2Y230.38%
EPS Next 3Y175.47%
EPS Next 5Y107.92%
Revenue Next Year18.91%
Revenue Next 2Y18.63%
Revenue Next 3Y19.2%
Revenue Next 5Y18.18%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. FOLD Valuation Analysis
4.1 Price/Earnings Ratio
- FOLD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- A Price/Forward Earnings ratio of 44.05 indicates a quite expensive valuation of FOLD.
- 90.94% of the companies in the same industry are more expensive than FOLD, based on the Price/Forward Earnings ratio.
- The average S&P500 Price/Forward Earnings ratio is at 24.39. FOLD is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 44.05 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of FOLD indicates a rather cheap valuation: FOLD is cheaper than 89.98% of the companies listed in the same industry.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of FOLD indicates a rather cheap valuation: FOLD is cheaper than 91.14% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 151.02 | ||
| EV/EBITDA | 108 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- FOLD's earnings are expected to grow with 175.47% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y230.38%
EPS Next 3Y175.47%
5. FOLD Dividend Analysis
5.1 Amount
- FOLD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
FOLD Fundamentals: All Metrics, Ratios and Statistics
14.36
-0.01 (-0.07%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-20 2026-02-20/amc
Earnings (Next)04-29 2026-04-29
Inst Owners101.15%
Inst Owner Change1.99%
Ins Owners0.55%
Ins Owner Change-8.02%
Market Cap4.51B
Revenue(TTM)634.21M
Net Income(TTM)-27.11M
Analysts71.43
Price Target15.81 (10.1%)
Short Float %5.81%
Short Ratio1.48
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-20.92%
Min EPS beat(2)-94.35%
Max EPS beat(2)52.51%
EPS beat(4)2
Avg EPS beat(4)-6.54%
Min EPS beat(4)-94.35%
Max EPS beat(4)52.51%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)0.26%
Min Revenue beat(2)0.02%
Max Revenue beat(2)0.49%
Revenue beat(4)3
Avg Revenue beat(4)-1.5%
Min Revenue beat(4)-9.62%
Max Revenue beat(4)3.12%
Revenue beat(8)5
Avg Revenue beat(8)-0.57%
Revenue beat(12)8
Avg Revenue beat(12)-0.07%
Revenue beat(16)10
Avg Revenue beat(16)-0.84%
PT rev (1m)0%
PT rev (3m)-5.8%
EPS NQ rev (1m)20.82%
EPS NQ rev (3m)27.46%
EPS NY rev (1m)0%
EPS NY rev (3m)19.01%
Revenue NQ rev (1m)0.26%
Revenue NQ rev (3m)-1.58%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.73%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 44.05 | ||
| P/S | 7.11 | ||
| P/FCF | 151.02 | ||
| P/OCF | 136.01 | ||
| P/B | 16.44 | ||
| P/tB | 72.09 | ||
| EV/EBITDA | 108 |
EPS(TTM)-0.08
EYN/A
EPS(NY)0.33
Fwd EY2.27%
FCF(TTM)0.1
FCFY0.66%
OCF(TTM)0.11
OCFY0.74%
SpS2.02
BVpS0.87
TBVpS0.2
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.85% | ||
| ROE | -9.89% | ||
| ROCE | 4.84% | ||
| ROIC | 3.83% | ||
| ROICexc | 6.51% | ||
| ROICexgc | 13.18% | ||
| OM | 5.44% | ||
| PM (TTM) | N/A | ||
| GM | 88.5% | ||
| FCFM | 4.71% |
ROA(3y)-9.83%
ROA(5y)-17.97%
ROE(3y)-44.48%
ROE(5y)-81.46%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.09%
GM growth 5Y0.1%
F-Score4
Asset Turnover0.67
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.43 | ||
| Debt/FCF | 13.15 | ||
| Debt/EBITDA | 9.36 | ||
| Cap/Depr | 44.18% | ||
| Cap/Sales | 0.52% | ||
| Interest Coverage | 0.79 | ||
| Cash Conversion | 79.01% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.84 | ||
| Quick Ratio | 1.88 | ||
| Altman-Z | 1.27 |
F-Score4
WACC8.94%
ROIC/WACC0.43
Cap/Depr(3y)60.08%
Cap/Depr(5y)62.67%
Cap/Sales(3y)1.02%
Cap/Sales(5y)1.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)58.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-90%
EPS Next Y534.7%
EPS Next 2Y230.38%
EPS Next 3Y175.47%
EPS Next 5Y107.92%
Revenue 1Y (TTM)20.05%
Revenue growth 3Y24.43%
Revenue growth 5Y19.44%
Sales Q2Q%23.72%
Revenue Next Year18.91%
Revenue Next 2Y18.63%
Revenue Next 3Y19.2%
Revenue Next 5Y18.18%
EBIT growth 1Y1.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year142.25%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y179.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y197.8%
OCF growth 3YN/A
OCF growth 5YN/A
AMICUS THERAPEUTICS INC / FOLD FAQ
What is the fundamental rating for FOLD stock?
ChartMill assigns a fundamental rating of 4 / 10 to FOLD.
What is the valuation status for FOLD stock?
ChartMill assigns a valuation rating of 5 / 10 to AMICUS THERAPEUTICS INC (FOLD). This can be considered as Fairly Valued.
Can you provide the profitability details for AMICUS THERAPEUTICS INC?
AMICUS THERAPEUTICS INC (FOLD) has a profitability rating of 4 / 10.
What is the expected EPS growth for AMICUS THERAPEUTICS INC (FOLD) stock?
The Earnings per Share (EPS) of AMICUS THERAPEUTICS INC (FOLD) is expected to grow by 534.7% in the next year.